• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Comparative Case Study of Efficacy of Oral Bilastine Monotherapy to Concomittant Administration of Oral Bilastine with Probiotic in Patients with Allergic Rhinitis.口服比拉斯汀单药治疗与口服比拉斯汀联合益生菌治疗变应性鼻炎患者的疗效比较病例研究
Indian J Otolaryngol Head Neck Surg. 2023 Sep;75(3):2137-2141. doi: 10.1007/s12070-023-03818-x. Epub 2023 Apr 29.
2
Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study.20毫克比拉斯汀与10毫克西替利嗪及安慰剂用于季节性变应性鼻炎症状治疗的疗效和安全性:一项随机、双盲、平行组研究
Clin Exp Allergy. 2009 Sep;39(9):1338-47. doi: 10.1111/j.1365-2222.2009.03257.x. Epub 2009 May 4.
3
Effectiveness of bilastine and fexofenadine among allergic Rhinitis patients in Ranchi, Jharkhand, India.比拉斯汀和非索非那定在印度贾坎德邦兰契过敏性鼻炎患者中的疗效
Bioinformation. 2022 Jun 30;18(6):596-599. doi: 10.6026/97320630018596. eCollection 2022.
4
Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients.20毫克比拉斯汀与5毫克地氯雷他定治疗季节性变应性鼻炎患者的疗效和安全性比较。
Allergy. 2009 Jan;64(1):158-65. doi: 10.1111/j.1398-9995.2008.01813.x.
5
Long-term safety and efficacy of bilastine following up to 12 weeks or 52 weeks of treatment in Japanese patients with allergic rhinitis: Results of an open-label trial.在日本过敏性鼻炎患者中进行长达12周或52周治疗后比拉斯汀的长期安全性和有效性:一项开放标签试验的结果。
Auris Nasus Larynx. 2017 Jun;44(3):294-301. doi: 10.1016/j.anl.2016.07.021. Epub 2016 Aug 22.
6
Comparison of the Efficacy and Safety of Bilastine 20 mg versus Fexofenadine 180 mg for Treatment of Perennial Allergic Rhinitis: Randomized Controlled Study.20毫克比拉斯汀与180毫克非索非那定治疗常年性变应性鼻炎的疗效和安全性比较:随机对照研究
Indian J Otolaryngol Head Neck Surg. 2024 Oct;76(5):4025-4030. doi: 10.1007/s12070-024-04770-0. Epub 2024 Jun 1.
7
Efficacy and Safety of Bilastine in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis.比拉斯汀治疗变应性鼻炎的疗效和安全性:一项系统评价和荟萃分析
Front Pharmacol. 2022 Jan 10;12:731201. doi: 10.3389/fphar.2021.731201. eCollection 2021.
8
Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review.根据 ARIA,评估比拉斯汀在变应性鼻炎治疗中的治疗地位:证据回顾。
Curr Med Res Opin. 2012 Jan;28(1):131-9. doi: 10.1185/03007995.2011.648263. Epub 2011 Dec 22.
9
Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis.比拉斯汀 20 毫克与西替利嗪 10 毫克和安慰剂治疗常年性变应性鼻炎的疗效和安全性比较。
Curr Med Res Opin. 2012 Jan;28(1):121-30. doi: 10.1185/03007995.2011.640667. Epub 2011 Nov 30.
10
A Study on the Significance of Nasal Smear Eosinophil Count and Blood Absolute Eosinophil Count in Patients with Allergic Rhinitis of Varied Severity of Symptoms.不同症状严重程度的变应性鼻炎患者鼻涂片嗜酸性粒细胞计数和血液嗜酸性粒细胞绝对值计数的意义研究
Indian J Otolaryngol Head Neck Surg. 2023 Dec;75(4):3449-3452. doi: 10.1007/s12070-023-03945-5. Epub 2023 Jun 27.

本文引用的文献

1
The burden of allergic diseases in the Indian subcontinent: barriers and challenges.印度次大陆过敏性疾病的负担:障碍与挑战。
Lancet Glob Health. 2020 Apr;8(4):e478-e479. doi: 10.1016/S2214-109X(20)30061-9.
2
Antihistamines for Allergic Rhinitis Treatment from the Viewpoint of Nonsedative Properties.抗组胺药治疗变应性鼻炎的非镇静作用观点。
Int J Mol Sci. 2019 Jan 8;20(1):213. doi: 10.3390/ijms20010213.
3
The Allergic Rhinitis - Clinical Investigator Collaborative (AR-CIC): nasal allergen challenge protocol optimization for studying AR pathophysiology and evaluating novel therapies.变应性鼻炎 - 临床研究者合作组织(AR-CIC):用于研究 AR 发病机制和评估新型疗法的鼻变应原挑战方案优化。
Allergy Asthma Clin Immunol. 2015 Apr 24;11(1):16. doi: 10.1186/s13223-015-0082-0. eCollection 2015.
4
Efficacy and safety of the probiotic Lactobacillus paracasei LP-33 in allergic rhinitis: a double-blind, randomized, placebo-controlled trial (GA2LEN Study).益生菌干酪乳杆菌 LP-33 治疗变应性鼻炎的疗效和安全性:一项双盲、随机、安慰剂对照试验(GA2LEN 研究)。
Eur J Clin Nutr. 2014 May;68(5):602-7. doi: 10.1038/ejcn.2014.13. Epub 2014 Feb 26.
5
Comparison of two oral probiotic preparations in a randomized crossover trial highlights a potentially beneficial effect of Lactobacillus paracasei NCC2461 in patients with allergic rhinitis.一项随机交叉试验比较了两种口服益生菌制剂,结果突出显示副干酪乳杆菌 NCC2461 对过敏性鼻炎患者可能具有有益作用。
Clin Transl Allergy. 2014 Jan 6;4(1):1. doi: 10.1186/2045-7022-4-1.
6
Allergy situation in India: what is being done?印度的过敏情况:正在采取哪些措施?
Indian J Chest Dis Allied Sci. 2013 Jan-Mar;55(1):7-8.
7
Oral availability of bilastine.比拉斯汀的口服生物利用度。
Clin Drug Investig. 2013 May;33(5):375-81. doi: 10.1007/s40261-013-0076-y.
8
The pathophysiology, diagnosis and treatment of allergic rhinitis.变应性鼻炎的病理生理学、诊断和治疗。
Allergy Asthma Immunol Res. 2010 Apr;2(2):65-76. doi: 10.4168/aair.2010.2.2.65. Epub 2010 Mar 24.
9
Probiotics for the prevention or treatment of allergic diseases.用于预防或治疗过敏性疾病的益生菌。
J Allergy Clin Immunol. 2007 Aug;120(2):255-62. doi: 10.1016/j.jaci.2007.04.027. Epub 2007 Jun 4.
10
Allergic rhinitis and its pharmacology.变应性鼻炎及其药理学
Pharmacol Ther. 2007 Jun;114(3):233-60. doi: 10.1016/j.pharmthera.2007.01.012. Epub 2007 Feb 28.

口服比拉斯汀单药治疗与口服比拉斯汀联合益生菌治疗变应性鼻炎患者的疗效比较病例研究

Comparative Case Study of Efficacy of Oral Bilastine Monotherapy to Concomittant Administration of Oral Bilastine with Probiotic in Patients with Allergic Rhinitis.

作者信息

U P Santosh, G B Ashwini, Chadha Baneet

机构信息

Department of Otorhinolarngology, J J M Medical College, Davangere, Karnataka India.

出版信息

Indian J Otolaryngol Head Neck Surg. 2023 Sep;75(3):2137-2141. doi: 10.1007/s12070-023-03818-x. Epub 2023 Apr 29.

DOI:10.1007/s12070-023-03818-x
PMID:37636707
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10447669/
Abstract

INTRODUCTION

Allergic rhinitis continues to pose a global burden in both adult and paediatric population and requires adequate medical therapy to avoid long term complications making it a challenging concern. This prompts the need to find a suitable and appropriate treatment regimen for this condition.

AIM

To study the clinical efficacy of Oral Bilastine and Probiotics in patients with allergic rhinitis. To compare the effectiveness of Bilastine monotherapy to Oral Bilastine combined with Probiotics in patients with allergic rhinitis.

MATERIALS AND METHODS

Total of 100 patients were selected and randomized into two groups- Group 1 and Group 2 and were treated with Oral Bilastine 20 mg OD and Oral Bilastine 20 mg with Oral Probiotics OD (Lactobacillus fermentum & L. paracasei - 4 billion cells) respectively to maintain uniformity. Baseline scoring and follow up scoring after 6 weeks was done using the Total symptom score, Absolute eosinophil count and Nasal smear eosinophil count and were evaluated and documented as per their response to treatment.

RESULTS

A significant reduction was observed in the severity of symptoms especially nasal obstruction, sneezing in patients of both groups along with extra nasal symptoms, with average mean score in Group 1 being 7.72 before treatment that reduced to 3.66 and that of Group 2 from 9.32 to 5.02. The mean score of Group 2 was greater in both before and after treatment which is highly significant. (p < 0.001).

CONCLUSION

Monotherapy with Oral Bilastine has proven in relieving allergic symptoms. Addition of Oral Probiotics along with Bilastine has shown to have synergistic effect in further improving overall symptoms in allergic rhinitis.

摘要

引言

过敏性鼻炎在成人和儿童群体中持续构成全球负担,需要适当的药物治疗以避免长期并发症,这使其成为一个具有挑战性的问题。这促使人们需要为这种疾病找到合适且恰当的治疗方案。

目的

研究口服比拉斯汀和益生菌对过敏性鼻炎患者的临床疗效。比较比拉斯汀单药治疗与口服比拉斯汀联合益生菌治疗过敏性鼻炎患者的有效性。

材料与方法

共选取100例患者,随机分为两组——第1组和第2组,分别给予口服比拉斯汀20毫克每日一次和口服比拉斯汀20毫克加口服益生菌每日一次(发酵乳杆菌和副干酪乳杆菌——40亿个细胞)以保持一致性。在治疗6周后,使用总症状评分、绝对嗜酸性粒细胞计数和鼻涂片嗜酸性粒细胞计数进行基线评分和随访评分,并根据其对治疗的反应进行评估和记录。

结果

两组患者的症状严重程度均有显著降低,尤其是鼻塞、打喷嚏以及鼻外症状,第1组治疗前平均评分为7.72,降至3.66,第2组从9.32降至5.02。第2组在治疗前后的平均评分均更高,差异具有高度显著性(p < 0.001)。

结论

口服比拉斯汀单药治疗已被证明可缓解过敏症状。比拉斯汀联合口服益生菌已显示出在进一步改善过敏性鼻炎总体症状方面具有协同作用。